Tumor BiologyPub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-3180
Yuankun Zhang, Qingxiao Song, Michael Lee, Haidong Tang, Kaniel Cassady, yang-xin fu, Dustin E. Schones, A. Riggs, Ru Feng, D. Zeng
{"title":"Abstract 3180: Blockade of PD-L1 interaction with CD80in transaugments anti-tumor immunity by increasing NOS2 in tumor-associated macrophages","authors":"Yuankun Zhang, Qingxiao Song, Michael Lee, Haidong Tang, Kaniel Cassady, yang-xin fu, Dustin E. Schones, A. Riggs, Ru Feng, D. Zeng","doi":"10.1158/1538-7445.AM2021-3180","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-3180","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43146583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-3039
R. Lock, K. Evans, Narimanne El-Zein, E. Earley, S. Erickson, B. Teicher, Malcolm A. Smith
{"title":"Abstract 3039: Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia","authors":"R. Lock, K. Evans, Narimanne El-Zein, E. Earley, S. Erickson, B. Teicher, Malcolm A. Smith","doi":"10.1158/1538-7445.AM2021-3039","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-3039","url":null,"abstract":"Introduction: While children with acute lymphoblastic leukemia (ALL) experience close to a 90% likelihood of cure, the outcome for certain high-risk pediatric ALL subtypes remains poor. Spleen Tyrosine Kinase (SYK), a cytosolic nonreceptor tyrosine kinase, is primarily expressed in the hematopoietic lineage and is essential for B-cell receptor signaling. It is associated with malignant transformation, cancer cell proliferation, and is a prominent tyrosine-phosphorylated protein in B-lineage pediatric ALL (Dolai et al, Cancer Res 76:2766-77, 2016). Fms Related Receptor Tyrosine Kinase 3 (FLT3) is a Class III receptor tyrosine kinase that regulates hematopoiesis. While uncommon in ALL, activating FLT3 mutations and internal tandem duplications are associated with poor outcome. TAK-659 is a dual SYK/FLT3 reversible inhibitor currently undergoing clinical trials against B-cell lymphoma, acute myeloid leukemia and solid tumors. Therefore, it was of interest for the Pediatric Preclinical Testing Consortium to test TAK-659 in vivo against its patient-derived xenograft (PDX) models of pediatric ALL. Methods: SYK and FLT3 mRNA expression in ALL PDXs was quantified by RNAseq (https://pedcbioportal.org) and 8 B-lineage pediatric ALL PDXs (3 B-cell precursor, BCP; 4 mixed-lineage leukemia-rearranged, MLLr; one Philadelphia Chromosome-like, Ph-like) were selected for testing. Engraftment was evaluated by enumerating the proportion of human CD45+ cells (%huCD45+) in the peripheral (PB) blood at weekly intervals. TAK-659 was tested at 60 mg/kg by oral gavage daily for 21 days. Events were defined as %huCD45+ ≥ 25%. At Day 28 post-treatment initiation or event (whichever occurred first), 4 mice/group were humanely killed to assess leukemia infiltration in the spleen and bone marrow (BM). Drug efficacy was assessed by event-free survival (EFS) of treated (T) and control (C) groups by T-C, T/C and stringent objective response measures (Houghton et al, Pediatr Blood Cancer 49:928-40, 2007). Results: The in vivo efficacy of TAK-659 was evaluated against B-lineage PDXs as FLT3 and SYK mRNA expression was higher in the PDXs from this lineage compared with PDXs from T-ALL. TAK-659 was well tolerated and significantly prolonged the time to event in 6/8 PDXs (T-C 0-25.5 days, T/C 1.0-2.2). Only one MLLr-ALL obtained an objective response (partial response) with all other models exhibiting progressive disease. The minimum mean %huCD45+ was significantly reduced in 5/8 PDXs in TAK-659 treated mice compared to control. Despite significant reductions in %huCD45+ in the PB for 5/8 PDXs, TAK-659 did not significantly reduce the spleen or BM infiltration of any PDXs. Conclusion: TAK-659 exhibited low to moderate single-agent in vivo activity against pediatric B-ALL PDXs representative of diverse disease subtypes. (Supported by NCI Grants CA199000 and CA199922) Citation Format: Richard B. Lock, Kathryn Evans, Narimanne El-Zein, Eric J. Earley, Stephen W. Erickson, Beverly A. Tei","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43207883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-3149
Beilei Liu
{"title":"Abstract 3149: Investigation of the potential therapeutic value of CAF-derived milk fat globule-EGF factor 8 protein (MFG-E8) in esophageal squamous cell carcinoma","authors":"Beilei Liu","doi":"10.1158/1538-7445.AM2021-3149","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-3149","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41989657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-3147
F. Barthel, N. Verburg, R. Rockne, R. Eijgelaar, K. Anderson, D. J. Müller, S. Branciamore, K. Johnson, P. Wesseling, P. D. W. Hamer, R. Verhaak
{"title":"Abstract 3147: Stereotactic image-guided epigenome profiling reveals a neural stem cell evolutionary origin of diffuse gliomas","authors":"F. Barthel, N. Verburg, R. Rockne, R. Eijgelaar, K. Anderson, D. J. Müller, S. Branciamore, K. Johnson, P. Wesseling, P. D. W. Hamer, R. Verhaak","doi":"10.1158/1538-7445.AM2021-3147","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-3147","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42241280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-2891
N. Li, Shile Huang
{"title":"Abstract 2891: Protein phosphatase 5 regulation of cell motility","authors":"N. Li, Shile Huang","doi":"10.1158/1538-7445.AM2021-2891","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2891","url":null,"abstract":"Metastasis has been considered as one of the cancer hallmarks. Approximately 90% of cancer-related death is due to cancer metastasis. Tumor cell migration is a prerequisite for cancer metastasis. Protein phosphatase 5 (PP5) is a serine/threonine protein phosphatase that belongs to the phosphoprotein phosphatase (PPP) family including PP1 and PP2A. It is well known that PP5 regulates apoptosis, proliferation, and stress response. However, the role of PP5 in the regulation of cell motility is only beginning to be recognized, and the mechanism of PP5 regulation of cell motility is largely unknown. In this study, our tissue microarray (TMA) studies showed the expression of PP5 increased with the stages of prostate cancer, which is consistent with the previous findings that there is a positive correlation between PP5 overexpression and breast cancer metastases. Furthermore, by the single-cell motility assay, we found that overexpression of PP5 increased the motility of various tumor cells, whereas knockdown of PP5 decreased the cell motility, suggesting that PP5 positively regulates cell motility. As focal adhesion kinase (FAK) is a key regulator of cell motility, and a report has shown that PP5 forms a complex with ASK1, FAK, CXCR4 in wounded alveolar epithelial cancer cells, we examined whether PP5 activates FAK. The Western blotting results showed that overexpression of PP5 did not obviously affect the phosphorylation of FAK. The results suggest that PP5 regulates cell motility through a new mechanism. Further research is on the way to identify how PP5 positively regulates cell motility. (Supported by the Feist-Weiller Cancer Center, LSU Health Sciences Center, Shreveport, LA, USA.) Citation Format: n Li, Shile Huang. Protein phosphatase 5 regulation of cell motility [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2891.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42267807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-2709
Fang Liu, Jun Zhou, Tanima Kundu-Roy, Joseph Wahler, J. So, Yong Lin, Y. Lou, N. Barnard, I. Matsuura, N. Suh
{"title":"Abstract 2709: CD44 inhibits DCIS progression to invasive carcinoma","authors":"Fang Liu, Jun Zhou, Tanima Kundu-Roy, Joseph Wahler, J. So, Yong Lin, Y. Lou, N. Barnard, I. Matsuura, N. Suh","doi":"10.1158/1538-7445.AM2021-2709","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2709","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49570385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-2727
Vasiliki Stravokefalou, D. Stellas, S. Karaliota, Bethany A. Nagy, T. Guerin, S. Kozlov, B. Felber, G. Pavlakis
{"title":"Abstract 2727: Heterodimeric IL-15 (hetIL-15) affects conventional dendritic cells and a distinct novel dendritic cell population in different mouse cancer models of breast and pancreatic cancer","authors":"Vasiliki Stravokefalou, D. Stellas, S. Karaliota, Bethany A. Nagy, T. Guerin, S. Kozlov, B. Felber, G. Pavlakis","doi":"10.1158/1538-7445.AM2021-2727","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2727","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49611457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-130
Ansam Sinjab, Guangchun Han, Warapen Treekitkarnmongkol, K. Hara, P. Brennan, M. Dang, Dapeng Hao, Ruiping Wang, E. Dai, H. Dejima, Jiexin Zhang, Elena P. Bogatenkova, B. Sánchez-Espiridión, K. Chang, Danielle R. Little, Samer Bazzi, L. Tran, K. Krysan, C. Behrens, D. Duose, E. Parra, M. G. Raso, L. Solis, J. Fukuoka, Jianjun Zhang, B. Sepesi, T. Cascone, L. Byers, D. Gibbons, Jichao Chen, S. Moghaddam, E. Ostrin, D. Rosen, J. Heymach, P. Scheet, S. Dubinett, I. Wistuba, J. Fujimoto, Christopher S Stevenson, A. Spira, Linghua Wang, H. Kadara
{"title":"Abstract 130: Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing","authors":"Ansam Sinjab, Guangchun Han, Warapen Treekitkarnmongkol, K. Hara, P. Brennan, M. Dang, Dapeng Hao, Ruiping Wang, E. Dai, H. Dejima, Jiexin Zhang, Elena P. Bogatenkova, B. Sánchez-Espiridión, K. Chang, Danielle R. Little, Samer Bazzi, L. Tran, K. Krysan, C. Behrens, D. Duose, E. Parra, M. G. Raso, L. Solis, J. Fukuoka, Jianjun Zhang, B. Sepesi, T. Cascone, L. Byers, D. Gibbons, Jichao Chen, S. Moghaddam, E. Ostrin, D. Rosen, J. Heymach, P. Scheet, S. Dubinett, I. Wistuba, J. Fujimoto, Christopher S Stevenson, A. Spira, Linghua Wang, H. Kadara","doi":"10.1158/1538-7445.AM2021-130","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-130","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42330859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-2837
M. Sosa, Carolina Rodriguez-Tirado, Nupura Kale, M. Carlini, N. Shrivastava, Bassem D. Khalil, J. Bravo-Cordero, Melissa Alexander, Jiayi Ji
{"title":"Abstract 2837: NR2F1 is a barrier to early dissemination of pre-malignant mammary cells","authors":"M. Sosa, Carolina Rodriguez-Tirado, Nupura Kale, M. Carlini, N. Shrivastava, Bassem D. Khalil, J. Bravo-Cordero, Melissa Alexander, Jiayi Ji","doi":"10.1158/1538-7445.AM2021-2837","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2837","url":null,"abstract":"Cancer cells disseminate during very early and sometimes asymptomatic stages of tumor progression. Granted that biological barriers to tumorigenesis exist, there must also be limiting steps to early dissemination, all of which remain largely unknown. We report that the orphan nuclear receptor NR2F1/COUP-TF1 serves as a barrier to early dissemination. High-resolution intravital imaging revealed that loss of function of NR2F1 in HER2+ early cancer cells increased in vivo dissemination without accelerating mammary tumor formation. NR2F1 expression was positively regulated by the tumor suppressive MMK3/6-p38-MAPK pathway and downregulated by HER2 and Wnt4 oncogenic signaling. NR2F1 downregulation by HER2 in early cancer cells led to decreased E-cadherin expression and β-catenin membrane localization, disorganized laminin 5 deposition, and increased expression of CK14, TWIST1, ZEB1 and PRRX1. Our findings reveal the existence of an inhibitory mechanism of dissemination regulated by NR2F1 downstream of HER2 signaling. Citation Format: Maria Soledad Sosa, Carolina Rodriguez-Tirado, Nupura Kale, Maria Carlini, Nitisha Shrivastava, Bassem Khalil, Javier Bravo-Cordero, Melissa Alexander, Jiayi Ji. NR2F1 is a barrier to early dissemination of pre-malignant mammary cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2837.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42565653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}